Home LiteratureArticle Details
PMID: 22731740 Published · epublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data.

BMC neurology ·Vol. 12 ·2012-06-25 ·Pages 46

Ye J, Farnum M, Yang E, Verbeeck R, Lobanov V, Raghavan N, Novak G, DiBernardo A, Narayan VA, Alzheimer’s Disease Neuroimaging Initiative

Abstract

Patients with Mild Cognitive Impairment (MCI) are at high risk of progression to Alzheimer's dementia. Identifying MCI individuals with high likelihood of conversion to dementia and the associated biosignatures has recently received increasing attention in AD research. Different biosignatures for AD (neuroimaging, demographic, genetic and cognitive measures) may contain complementary information for diagnosis and prognosis of AD. We have conducted a comprehensive study using a large number of samples from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to test the power of integrating various baseline data for predicting the conversion from MCI to probable AD and identifying a small subset of biosignatures for the prediction and assess the relative importance of different modalities in predicting MCI to AD conversion. We have employed sparse logistic regression with stability selection for the integration and selection of potential predictors. Our study differs from many of the other ones in three important respects: (1) we use a large cohort of MCI samples that are unbiased with respect to age or education status between case and controls (2) we integrate and test various types of baseline data available in ADNI including MRI, demographic, genetic and cognitive measures and (3) we apply sparse logistic regression with stability selection to ADNI data for robust feature selection. We have used 319 MCI subjects from ADNI that had MRI measurements at the baseline and passed quality control, including 177 MCI Non-converters and 142 MCI Converters. Conversion was considered over the course of a 4-year follow-up period. A combination of 15 features (predictors) including those from MRI scans, APOE genotyping, and cognitive measures achieves the best prediction with an AUC score of 0.8587. Our results demonstrate the power of integrating various baseline data for prediction of the conversion from MCI to probable AD. Our results also demonstrate the effectiveness of stability selection for feature selection in the context of sparse logistic regression.

MeSH Terms
Aged Algorithms Alzheimer Disease/diagnosis,etiology Artificial Intelligence Cognitive Dysfunction/complications,diagnosis Decision Support Systems, Clinical Diagnosis, Computer-Assisted/methods Female Humans Male Proportional Hazards Models Reproducibility of Results Sensitivity and Specificity
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Ye Jieping
Center for Evolutionary Medicine and Informatics, The Biodesign Institute, Arizona, State University, Tempe, AZ, USA. [email protected]
Farnum Michael
Yang Eric
Verbeeck Rudi
Lobanov Victor
Raghavan Nandini
Novak Gerald
DiBernardo Allitia
Narayan Vaibhav A
Alzheimer’s Disease Neuroimaging Initiative
References (30)
30 references, click to expand
  1. Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients.
    Radiology. 2008 Aug;248(2):590-8 PMID: 18574133
  2. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.
    Ann Neurol. 2000 Apr;47(4):430-9 PMID: 10762153
  3. Neuropathological stageing of Alzheimer-related changes.
    Acta Neuropathol. 1991;82(4):239-59 PMID: 1759558
  4. Small baseline volume of left hippocampus is associated with subsequent conversion of MCI into dementia: the Göteborg MCI study.
    J Neurol Sci. 2008 Sep 15;272(1-2):48-59 PMID: 18571674
  5. Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve.
    Brain. 2009 Aug;132(Pt 8):2036-47 PMID: 19439419
  6. Differential regional atrophy of the cingulate gyrus in Alzheimer disease: a volumetric MRI study.
    Cereb Cortex. 2006 Dec;16(12):1701-8 PMID: 16400164
  7. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.
    J Magn Reson Imaging. 2008 Apr;27(4):685-91 PMID: 18302232
  8. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease.
    Neurology. 1992 Jan;42(1):183-8 PMID: 1734300
  9. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI.
    Neuroimage. 2009 Feb 15;44(4):1415-22 PMID: 19027862
  10. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Neurology. 2001 May 8;56(9):1133-42 PMID: 11342677
  11. Visualisation and quantification of rates of atrophy in Alzheimer's disease.
    Lancet. 1996 Jul 13;348(9020):94-7 PMID: 8676724
  12. The cerebellum in mild cognitive impairment and Alzheimer's disease - a structural MRI study.
    J Psychiatr Res. 2008 Oct;42(14):1198-202 PMID: 18215400
  13. Phases of A beta-deposition in the human brain and its relevance for the development of AD.
    Neurology. 2002 Jun 25;58(12):1791-800 PMID: 12084879
  14. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.
    Neurology. 2007 Mar 13;68(11):828-36 PMID: 17353470
  15. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
    Ann Neurol. 2009 Apr;65(4):403-13 PMID: 19296504
  16. Mild cognitive impairment clinical trials.
    Nat Rev Drug Discov. 2003 Aug;2(8):646-53 PMID: 12904814
  17. Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry.
    J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):657-64 PMID: 12438466
  18. Brain metabolism in the cerebellum and visual cortex correlates with neuropsychological testing in patients with Alzheimer's disease.
    Nucl Med Commun. 2003 Jul;24(7):785-90 PMID: 12813197
  19. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease.
    Alzheimer Dis Assoc Disord. 2011 Jan-Mar;25(1):73-84 PMID: 20847637
  20. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.
    J Neurosci. 2010 Feb 10;30(6):2088-101 PMID: 20147537
  21. Structural MRI biomarkers for preclinical and mild Alzheimer's disease.
    Hum Brain Mapp. 2009 Oct;30(10):3238-53 PMID: 19277975
  22. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD.
    Neurobiol Aging. 2004 Mar;25(3):303-10 PMID: 15123335
  23. Assessing the onset of structural change in familial Alzheimer's disease.
    Ann Neurol. 2003 Feb;53(2):181-8 PMID: 12557284
  24. 2010 Alzheimer's disease facts and figures.
    Alzheimers Dement. 2010 Mar;6(2):158-94 PMID: 20298981
  25. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study.
    Neurology. 2007 Nov 6;69(19):1859-67 PMID: 17984454
  26. Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment.
    J Neurol Neurosurg Psychiatry. 2002 Apr;72(4):491-7 PMID: 11909909
  27. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification.
    Neurobiol Aging. 2011 Dec;32(12):2322.e19-27 PMID: 20594615
  28. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations.
    Neurology. 2009 Jul 28;73(4):287-93 PMID: 19636048
  29. Cerebellar atrophy in Alzheimer's disease-clinicopathological correlations.
    Brain Res. 1999 Feb 6;818(1):41-50 PMID: 9914436
  30. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.
    Arch Neurol. 2010 Aug;67(8):949-56 PMID: 20697045
Article Info
Journal
BMC neurology
Abbr.
BMC Neurol
ISSN
1471-2377
Published
2012-06-25
Epub
2012-00-25
Pages
46
Language
English
Region
England
NLM ID
100968555
PMCID
PMC3477025
Subset
IM
Grants
NIA NIH HHS · P30 AG010129 · United States
NIA NIH HHS · U19 AG010483 · United States
CIHR · Canada
NIA NIH HHS · U01 AG024904 · United States
NIA NIH HHS · K01 AG030514 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]